Terminated PHASE2 INTERVENTIONAL 3-arm NCT05591222

Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Investigate the Efficacy and Safety of Daxdilimab Subcutaneous Injection in Reducing Disease Activity in Adult Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus

Sponsor: Amgen

Conditions Discoid Lupus Erythematosus

Interventions Daxdilimab Placebo

Updated 21 times since 2022 Last updated: Oct 18, 2025 Started: Dec 29, 2022 Primary completion: May 8, 2025 Completion: May 8, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor business decision, not related to safety concerns.

Other terminated trials from Amgen

See all terminations from Amgen

Listed as NCT05591222, this PHASE2 trial focuses on Discoid Lupus Erythematosus and remains terminated or withdrawn. Sponsored by Amgen, it has been updated 21 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

21 versions recorded

Nov 2025 — Present [monthly]

Terminated PHASE2
Sep 2025 — Nov 2025 [monthly]

Terminated PHASE2
Jul 2025 — Sep 2025 [monthly]

Terminated PHASE2

Status: Active Not Recruiting → Terminated
Apr 2025 — Jul 2025 [monthly]

Active Not Recruiting PHASE2
Mar 2025 — Apr 2025 [monthly]

Active Not Recruiting PHASE2

▶ Show 16 earlier versions

Nov 2024 — Mar 2025 [monthly]

Active Not Recruiting PHASE2
Oct 2024 — Nov 2024 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
May 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Mar 2024 — May 2024 [monthly]

Recruiting PHASE2
Jan 2024 — Mar 2024 [monthly]

Recruiting PHASE2
Nov 2023 — Jan 2024 [monthly]

Recruiting PHASE2
Sep 2023 — Nov 2023 [monthly]

Recruiting PHASE2
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE2
Jun 2023 — Aug 2023 [monthly]

Recruiting PHASE2
May 2023 — Jun 2023 [monthly]

Recruiting PHASE2
Apr 2023 — May 2023 [monthly]

Recruiting PHASE2
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE2
Feb 2023 — Mar 2023 [monthly]

Recruiting PHASE2
Nov 2022 — Feb 2023 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen

Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Athens, Greece , Berlin, Germany , Beverly Hills, United States , Brno, Czechia , Campinas, Brazil , Caxias do Sul, Brazil , Ciudad Autonoma Buenos Aires, Argentina , Columbus, United States , Copenhagen NV, Denmark , Dresden, Germany and 49 more locations